These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37461815)

  • 1. Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination.
    Callegari C; Lazzarotto D; Soravia A; Mutti M; Lauzzana P; Peghin M; Cordella S; Fanin R; Candoni A
    Eur J Haematol; 2023 Oct; 111(4):668-670. PubMed ID: 37461815
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration.
    Funakoshi Y; Yakushijin K; Ohji G; Matsutani T; Hojo W; Sakai H; Matsumoto S; Watanabe M; Kitao A; Saito Y; Kawamoto S; Yamamoto K; Koyama T; Nagatani Y; Kimbara S; Imamura Y; Kiyota N; Ito M; Minami H
    Br J Haematol; 2023 Aug; 202(3):504-516. PubMed ID: 37349876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
    Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
    J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
    Reimann P; Petzer V; Mündlein A; Hartmann B; Severgnini L; Winkler A; Lang T; Huynh M; Gasser K; Rüger J; Atzl M; Mink S; Fraunberger P; Schmidt S; Steiner N; Griesmacher A; Gunsilius E; Nachbaur D; Willenbacher W; Wolf D; Winder T; Benda MA
    Ann Hematol; 2024 Jun; 103(6):2123-2131. PubMed ID: 38436671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
    Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
    Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
    Angotzi F; Petrella M; Berno T; Binotto G; Bonetto G; Branca A; Carraro M; Cavaretta CA; Cellini A; D'Amore F; Forlani L; Gianesello I; Gurrieri C; Imbergamo S; Lessi F; Maroccia A; Mazzetto F; Pavan L; Pezone S; Piazza F; Pravato S; Ruocco V; Scapinello G; Vianello F; Zambello R; Zatta I; Zoletto S; Padoan A; Trentin L; Visentin A
    Front Oncol; 2023; 13():1212752. PubMed ID: 37427126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
    Shao Y; Zhou Y
    Haematologica; 2023 Feb; 108(2):653-654. PubMed ID: 36172816
    [No Abstract]   [Full Text] [Related]  

  • 10. High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination.
    Shapiro LC; Thakkar A; Gali R; Gonzalez-Lugo JD; Bazarbachi AH; Rahman S; Pradhan K; Fehn K; Abreu M; Kornblum N; Gritsman K; Goldfinger M; Shastri A; Mantzaris I; Braunschweig I; Halmos B; Verma A; McCort M; Bachier-Rodriguez L; Sica RA
    Leuk Lymphoma; 2022 Oct; 63(10):2484-2488. PubMed ID: 35593019
    [No Abstract]   [Full Text] [Related]  

  • 11. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.
    Haggenburg S; Hofsink Q; Rutten CE; Nijhof IS; Hazenberg MD; Goorhuis A
    Semin Hematol; 2022 Oct; 59(4):192-197. PubMed ID: 36805887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants.
    Kamboj M; Laracy JC; Usiak S; Babady NE; Yan J; Seo SK
    J Infect; 2023 Sep; 87(3):282-285. PubMed ID: 37451364
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
    Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
    Front Immunol; 2022; 13():892331. PubMed ID: 36003404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tixagevimab + Cilgavimab: First Approval.
    Keam SJ
    Drugs; 2022 Jun; 82(9):1001-1010. PubMed ID: 35727563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies.
    Ni B; Yanis A; Dee K; Chappell JD; Dulek DE; Kassim AA; Kitko CL; Thomas LD; Halasa N
    Blood Rev; 2022 Nov; 56():100984. PubMed ID: 35752546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.
    Hoff FW; Goksu SY; Premnath N; Patel PA; Ikpefan R; Kaur G; Vusirikala M; Bat T; Chen W; Geethakumari PR; Anderson LD; Awan FT; Collins RH; Weinberg OK; Muthukumar A; Chung SS; Madanat YF
    Acta Med Acad; 2023 Apr; 52(1):30-36. PubMed ID: 37326395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
    Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
    mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
    Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
    J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era.
    Zerbit J; Detroit M; Meyer A; Decroocq J; Deau-Fischer B; Deschamps P; Birsen R; Mondesir J; Franchi P; Miekoutima E; Guerin C; Batista R; Bouscary D; Willems L; Vignon M
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
    Gagelmann N; Passamonti F; Wolschke C; Massoud R; Niederwieser C; Adjallé R; Mora B; Ayuk F; Kröger N
    Haematologica; 2022 Aug; 107(8):1840-1849. PubMed ID: 34911284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.